Pascal Deschatelets Sells 909 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Pascal Deschatelets sold 909 shares of Apellis Pharmaceuticals stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $19.79, for a total value of $17,989.11. Following the transaction, the insider owned 1,157,310 shares in the company, valued at approximately $22,903,164.90. This represents a 0.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Pascal Deschatelets also recently made the following trade(s):

• On Tuesday, January 13th, Pascal Deschatelets sold 2,277 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $22.19, for a total transaction of $50,526.63.

Apellis Pharmaceuticals Price Performance

Shares of APLS stock opened at $22.00 on Friday. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.54 and a quick ratio of 3.10. The firm’s 50-day moving average is $22.99 and its two-hundred day moving average is $23.49. Apellis Pharmaceuticals, Inc. has a 12 month low of $16.10 and a 12 month high of $31.17. The company has a market capitalization of $2.78 billion, a PE ratio of 70.97 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.64. The business had revenue of $458.58 million during the quarter, compared to analysts’ expectations of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The business’s revenue for the quarter was up 133.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.46) EPS. Analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS from Neutral to Buy, citing a stronger-than-expected launch trajectory for the company’s newly approved kidney-disease therapy and assigning a $28 price target — signaling notable upside if commercial momentum continues. Apellis upgraded at BofA on launch trajectory for kidney disease therapy
• Positive Sentiment: An analyst note argues Apellis’s current valuation understates Empaveli’s (the newly approved rare-kidney-disease drug) revenue potential after early uptake, supporting a re-rating if prescriptions and payor access scale. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (reducing upside expectations) but kept an Overweight stance — a mixed institutional signal that still leaves the company supported by some buy-side analysts. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, which is neutral for near-term flows and may cap upside for investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: A cluster of insider sales on Jan. 20 (including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and other officers) has been disclosed via Form 4 filings — a coordination of sales that can hurt sentiment even if sales are routine diversification. See CEO filing for details. CEO Cedric Francois Form 4

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its position in shares of Apellis Pharmaceuticals by 0.8% during the second quarter. PNC Financial Services Group Inc. now owns 58,856 shares of the company’s stock worth $1,019,000 after purchasing an additional 465 shares in the last quarter. Wedmont Private Capital grew its holdings in shares of Apellis Pharmaceuticals by 4.1% in the fourth quarter. Wedmont Private Capital now owns 11,883 shares of the company’s stock valued at $315,000 after purchasing an additional 468 shares in the last quarter. Amalgamated Bank increased its stake in Apellis Pharmaceuticals by 6.9% during the 3rd quarter. Amalgamated Bank now owns 8,674 shares of the company’s stock worth $196,000 after buying an additional 563 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Apellis Pharmaceuticals by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock worth $84,000 after buying an additional 655 shares during the period. Finally, Parallel Advisors LLC lifted its holdings in Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after buying an additional 855 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wells Fargo & Company decreased their price target on Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating on the stock in a research note on Tuesday. Cantor Fitzgerald reduced their price objective on shares of Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating on the stock in a report on Tuesday, January 13th. Bank of America raised shares of Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Wednesday. The Goldman Sachs Group reiterated a “sell” rating and set a $19.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, January 12th. Finally, Needham & Company LLC reduced their price target on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. Twelve analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.53.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.